prostate-specific membrane antigen

You have access
⁶⁸Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment
Farshad Moradi, Heying Duan, Hong Song, Guido A Davidzon, Benjamin I Chung, Alan E C Thong, Andreas M Loening, Pejman Ghanouni, Geoffrey Sonn and Andrei Iagaru

Journal of Nuclear Medicine May 5, 2022, jnumed.122.263897; DOI: https://doi.org/10.2967/jnumed.122.263897
You have access
A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Monica Abghari-Gerst, Wesley R. Armstrong, Kathleen Nguyen, Jeremie Calais, Johannes Czernin, David Lin, Namasvi Jariwala, Melissa Rodnick, Thomas A. Hope, Jason Hearn, Jeffrey S. Montgomery, Ajjai Alva, Zachery R. Reichert, Daniel E. Spratt, Timothy D. Johnson, Peter J.H. Scott and Morand Piert

Journal of Nuclear Medicine April 1, 2022, 63 (4) 567-572; DOI: https://doi.org/10.2967/jnumed.121.262412
You have access
Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer
William Gondoputro, Matthijs J Scheltema, Alexander Blazevski, Paul Doan, James E. Thompson, Amer Amin, Bart Geboers, Shikha Agrawal, Amila R. Siriwardana, Pim J. van Leeuwen, Matthias N van Oosterom, Fijs N van Leeuwen, Louise M. Emmett and Phillip D Stricker

Journal of Nuclear Medicine March 3, 2022, jnumed.121.263743; DOI: https://doi.org/10.2967/jnumed.121.263743
You have access
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Baijun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, Kenneth J. Pienta, Wei Xue and Steven P. Rowe

Journal of Nuclear Medicine February 1, 2022, 63 (2) 248-252; DOI: https://doi.org/10.2967/jnumed.121.262411
You have access
Kidney Doses in ¹⁷⁷Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer and Juri Ruf

Journal of Nuclear Medicine February 1, 2022, 63 (2) 253-258; DOI: https://doi.org/10.2967/jnumed.121.262245
You have access
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin

Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
You have access
Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand

Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
You have access
Head-to-Head Comparison of ⁶⁸Ga-NOTA (⁶⁸Ga-NGUL) and ⁶⁸Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon

Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434
You have access
Effects of ²²⁵Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis
Dong Yun Lee and Yong-il Kim

Journal of Nuclear Medicine September 9, 2021, jnumed.121.262017; DOI: https://doi.org/10.2967/jnumed.121.262017
You have access
Positive Predictive Value and Correct Detection Rate of ¹⁸F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein, Stephan G. Nekolla, Kilian Schiller, Matthias M. Heck, Tobias Maurer, Alexander Wurzer, Hans-Juergen Wester, Calogero D’Alessandria, Wolfgang Weber and Matthias Eiber

Journal of Nuclear Medicine July 1, 2021, 62 (7) 968-974; DOI: https://doi.org/10.2967/jnumed.120.255661

Main menu

User menu

Search

prostate-specific membrane antigen

Pages